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ABSTRACT
The rapid progress in next-generation sequencing technologies has significantly 
contributed to our knowledge of the genetic events associated with the development, 
progression and treatment resistance of chronic lymphocytic leukemia patients. 
Together with the discovery of new driver mutations, next-generation sequencing 
has revealed an immense degree of both intra- and inter-tumor heterogeneity and 
enabled us to describe marked clonal evolution. Advances in immunogenetics may be 
implemented to detect minimal residual disease more sensitively and to track clonal 
B cell populations, their dynamics and molecular characteristics. The interpretation 
of these aspects is indispensable to thoroughly examine the genetic background of 
chronic lymphocytic leukemia. We review and discuss the recent results provided by 
the different next-generation sequencing techniques used in studying the chronic 
lymphocytic leukemia genome, as well as future perspectives in the methodologies 
and applications.
The emergence of next-generation sequencing in 
the field of the chronic lymphocytic leukemia
Chronic Lymphocytic Leukemia (CLL) is a disease 
that displays extreme clinical heterogeneity [1]. This 
heterogeneity reflexes CLL’s marked molecular diversity 
[2], the analysis of which has led to the identification of 
a handful of biomarkers. Despite the significant progress 
in developing therapeutic options in CLL (extensively 
reviewed in [3, 4]), which has improved patient survival, 
CLL remains largely incurable and its course difficult 
to predict. Hence, the need to understand the disease’s 
heterogeneous features is essential in order to characterize 
each CLL case and eventually proceed to more tailor-made 
therapeutic approaches. The technological advancements 
emerging in the field of molecular analyses are providing 
the tools which will allow this to be done.
Next-generation sequencing technologies (NGS) 
have brought into play an unpreceded analytical depth 
to accommodate the characterization of the highly 
complicated genetic landscape of hematological cancers, 
with the case in point being CLL. Since the publication 
of the first complete cancer genome, obtained from a 
patient with acute myeloid leukemia [5], many groups 
have utilized NGS to further elucidate the biology 
of hematologic malignancies. These in turn have 
resulted in the assembly of large consortia such as the 
International Cancer Genome Consortium (ICGC) [6] 
and The Cancer Genome Atlas (TCGA) Research 
Network [7].
                                                                               Review
Oncotarget71235www.impactjournals.com/oncotarget
A glance back to the recent research on the 
elucidation of CLL genomics is enough to prove the 
usefulness of NGS technologies by virtue of the discovery 
of new drivers, including mutations in non-coding regions, 
and the elucidation of signaling pathways whose role was 
previously unknown or poorly understood [8–10].
Although CLL was originally considered a 
genetically stable disease, we now know that new genetic 
aberrations are acquired during clonal evolution and are 
characteristic of CLL development and relapse. NGS data 
have facilitated the detection of several tumoral subclones 
per sample and have illustrated different patterns of clonal 
evolution [2]. In addition, genetic loci can be sequenced in 
great depth and mutations existing at very low subclonal 
levels can be identified [11, 12]. The clones bearing these 
mutations can then be tracked during disease development 
and relapse after therapy.
Sequencing a specific genomic region in great depth 
also makes it possible to analyze the antibody repertoire 
more thoroughly, enabling a deeper understanding of the 
immune system with respect to the immunogenetic B cell 
features [13–15].
NGS allows us to explore the molecular pathways 
involved in disease pathogenesis and enables us to propose 
new genes which could be targeted for therapeutic purposes. 
Genes discovered using this approach may subsequently 
be included in prognostication gene panels, which in turn 
would ensure great coverage depth maximizing the results’ 
clinical utility. Figure 1 summarizes the most prominent 
discoveries in CLL in this “NGS era” and describes how 
the different experimental set-ups can assist in finding 
answers to various scientific questions.
Here, we review the recent insights of the various 
NGS studies in CLL, paying particular attention to the use 
of this method to give us a profound understanding of the 
disease and its clinical applications.
Applications of NGS to the study of the CLL 
genome
Whole-genome sequencing (WGS) and whole-exome 
sequencing (WES) data are now available for extended 
patient series with more than 800 published CLL exomes or 
genomes [2, 8–10, 16–21], Landau et al. and Puente et al. 
are amongst the studies  providing the most comprehensive 
exploration of CLL’s mutational landscape. These NGS 
approaches have revealed a vast genetic heterogeneity in 
CLL patients with a small number of genes mutated in 
approximately 10–15% of cases, and a large number of 
genes mutated at a lower frequency (< 10%) (intertumoral 
genetic heterogeneity). In parallel, as NGS enables the 
genome-wide detection of mutations between tumor cells, 
the genetic heterogeneity within malignant cells of the 
same patient (intratumoral heterogeneity) has also been 
accessed. Compared with solid tumors [22], CLL with a 
mutation rate of 0.60-0.87/Mb is a low genomic-complex 
disease with an average of 15.3-26.9 somatic mutations per 
patient, according to Landau et al. [10] and Puente et al 
[9], respectively. The early WGS/WES studies not only 
corroborated known CLL-associated alterations, such as 
somatic mutations in TP53 and ATM, but also described 
a number of novel somatically mutated genes [8, 16, 17]. 
Amongst them, NOTCH1 and SF3B1 were identified as 
the most recurrently mutated genes with relatively higher 
frequencies than other candidates such as MYD88, POT1, 
CHD2, XPO1, BIRC3, FBXW7 and DDX3X. Moreover, 
the most recent studies have increased the number 
of recurrently mutated genes, identifying previously 
unrecognized genes [9, 10]. It is noteworthy to mention 
some of them, such as RPS15 [23], EGR2 [24], NFKBIE 
[25] and SETD2 [26]. The comparison between the two 
large cohort studies [9, 10] resulted in a significant overlap 
of 29 commonly mutated driver genes (Figure 2) albeit 
with existing discrepancies; the mutation frequencies were 
marked variable within common genes, and even some 
genes were exclusive of each study. These differences could 
be related to each cohort’s clinical characteristics: Puente 
et al. [9] analyzed only untreated CLL samples whereas 
over 6% of the patients were treated before the sequencing 
in Landau et al [10]. Another reason could be the different 
bioinformatics algorithms used in each study for variant 
calling as well as the definition of a mutated gene as a 
driver. It has been reported that the list of significantly 
mutated genes is different depending on the chosen 
computational method [27]. Incrementing the number of 
CLL cases analyzed by WGS or WES will identify even 
more significant mutated genes. Based on a saturation 
analysis and taking into account CLL background mutation 
rate, it has been estimated that an analysis of ~2000 samples 
would be enough to confidently identify recurrent mutated 
genes present in 1–2% of CLL patients [28].
Whereas WES provides information about coding 
DNA regions, WGS allows extensive detection of 
all abnormalities including non-coding regions. The 
application of WGS has led to the discovery of the most 
frequent recurrent non-coding mutation located in the 3′ 
untranslated region of NOTCH1 [9]. This splicing event 
is predicted to increase the stability of the NOTCH1 
protein [9]. Furthermore, a small intergenic region of 
chromosome 9p13 was enriched for somatic mutations 
resulting in the reduced expression of the B-cell-specific 
transcription factor PAX5 [9].
The large-scale comprehensive genetic 
characterization of CLL samples by WES and WGS 
studies has allowed us to better characterize the cell 
signaling pathways deregulated in CLL. Eight key cellular 
pathways (RNA metabolism, DNA damage, cell cycle 
control, apoptosis, NOTCH1 signaling, genome/chromatin 
structure, inflammatory pathway, B-cell signaling) have 
been described as recurrently mutated at different levels 
(Figure 2) [9, 10]. The emergence of NGS methodologies 
has also led to the discovery and extensive annotation 
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of CLL driver genes implicated in previously unknown 
CLL-related pathways such as RNA metabolism (SF3B1, 
XPO1, RPS15, MGA, DDX3X, FUBP1, MED12, NXF1). 
After an explosive growth in our understanding of CLL 
genetics, now it is time to assess the biological impact of 
the somatic mutations and how they affect cellular fitness. 
In this line, the biological relevance of some of them, 
such as mutations in POT1, CHD2, MED12, SAMHD1, 
has been further explored by functional analyses [29–32].
A particular pathway might be further analyzed in 
detail by targeted resequencing using a panel of chosen 
genes. Such a study involving the mutational screening 
of 18 core complex genes within the NF-κB pathway 
was performed in a cohort containing 315 cases and 
in concordance with the previous study, NFKBIE was 
found to be the most frequently mutated gene. It was 
further shown that the mutations were associated with 
inferior outcome [25]. On the same line, targeted NGS 
was employed on 9 genes related to the p53 pathway 
in a cohort of 180 CLL patients [33], and the identified 
mutations’ impact on the transcriptional activation of p53 
target genes was explored. 
Genome-wide sequencing strategies have revealed 
novel candidate CLL driver genes within regions of 
copy number alterations. Apart from the known TP53/
del(17p13) and ATM-BIRC3/del(11q22-23) associations, 
new regions have recently been identified, such as SETD2/
del(3p21), NFKB2/del(10q24), MGA/del(15q15.1) 
[9, 10]. New structural variations have also been reported, 
particularly structural rearrangements on chromosome 1, 
2, 13, and 14 [9, 20]. Surprisingly, a small subset of CLL 
had complex rearrangements such as chromothripsis and 
chromoplexy [9, 20, 34].
An additional benefit to applying NGS approaches 
to the study of large cohorts is the enhanced power to 
explore the relationships between driver lesions based on 
the patterns of their co-occurrence. This analysis revealed 
significant relationships between several alterations, 
including not only the already known high co-occurrence 
of NOTCH1 mutations/chromosome 12 trisomy, but also 
the previously undescribed high co-occurrence between 
mutations in BIRC3 and trisomy 12, mutations in SF3B1 
and POT1, as well as mutations in NOTCH1 and MGA. 
Other alterations, such as del(13q) with trisomy 12, co-occur 
less frequently [9, 10]. While interactions between genetic 
alterations could synergistically act to enhance tumor 
growth, lack of co-occurrence could indicate that alterations 
have highly similar downstream effects, and hence would 
lack further evolutionary advantage to the tumor cell.
NGS to study clonal evolution in CLL
Genome-wide sequencing studies have also shed 
light on CLL pathogenesis. CLL is preceded by a pre-
malignant state known as B-cell lymphocytosis (MBL). 
MBL was shown to carry mutations in some CLL drivers, 
and  the existence of clonal evolution was associated with 
a shorter progression time to CLL [35, 36]. MBL cases 
Figure 1: Timeline of the most relevant facts discovered in CLL by NGS studies.
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have a lower driver alteration burden than CLL patients, 
consistent with a model in which MBL-to-CLL evolution 
is accomplished by the progressive accumulation of driver 
alterations [9]. Regarding the origin of this disease, further 
studies by NGS are still necessary to clarify the cell of 
origin since few recent studies have suggested that CLL 
genetic alterations are present not only in B lymphocytes 
but also in hematopoietic progenitors [37, 38].
NGS studies have revealed the conspicuous presence 
of multiple genetically defined subpopulations that fuel 
diverse evolution patterns. Primarily, two common clonal 
evolution patterns have been observed in CLL patients: 
linear evolution, in which one dominant clone acquires 
driver events over time, and branched evolution, in which 
several tumoral subclones coexist and evolve over time 
[2, 19]. In this line, WGS showed different temporal 
Figure 2: Percentages of samples affected by mutations in common CLL drivers from Puente et al. [9] (blue) and Landau 
et al. [10] (red) studies. Genes were marked with different symbols according to the biological pathways involved.
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repopulation patterns after therapy that deviate from a 
stable equilibrium among subpopulations, to marked 
shifts in which one minor subclone entirely replaced the 
dominant clone over time [19]. In a further investigation, 
WES data were analyzed using a computational approach 
to infer subclonal populations through integrating 
allelic fraction information about somatic mutations 
with local copy number and sample purity. This study 
demonstrated that genetic subclonal population features 
are linked to poorer clinical outcome, implying that an 
active evolutionary process is the underlying basis of an 
aggressive disease [2]. A temporal order of clonal and 
subclonal mutations corresponding to earlier and later 
events was suggested, in which the copy number variations 
such as 13q deletion and trisomy 12 were identified as 
consistently clonal early events while mutations in ATM, 
BIRC3 or TP53  were identified as subclonal later genetic 
alterations [2, 10]. Regarding biallelic inactivation of 
the ATM, a clonal del(11q) used to appear earlier than 
mutations in ATM which affects the remaining allele as a 
second hit [10].
The absence of an intervening therapy was 
largely associated with stable subclonal composition 
over time [39]. In contrast, chemotherapy exposure 
predominantly resulted in marked clonal evolution. 
WES data on matched samples collected at the 
time of first progression and relapse of fludarabine, 
cyclophosphamide, and rituximab (FCR) therapy have 
revealed large clonal shifts between pre-treatment 
and relapse samples in the majority of cases [10] and 
a recurrent mutation in RPS15 in a large proportion of 
relapsed CLL cases [23]. Recently, WES was used to 
demonstrate that CLL patients with acquired resistance to 
ibrutinib therapy could not only have mutations in BTK at 
the binding site of ibrutinib or its immediate downstream 
partner PLCy2 [40] but also other potential alternative 
resistance mechanisms, such as del(8p) with additional 
driver mutations [41]. 
In order to monitor disease initiation, progression 
and relapse, it is important to define which clones are 
most biologically and clinically relevant. Targeted deep 
sequencing allows us to determine whether or not the 
driver mutations responsible for progression or relapse 
are already present in very small subclones at diagnosis. 
Longitudinal studies have already shown that the majority 
of driver mutations are already present in the initial stages, 
often as small subclones [10, 42–44]. Nevertheless, the 
clonal competition between the individual subclones 
carrying different mutations is a highly-complex process 
and mutations in the same gene can be selected in one 
patient and counter-selected in another [44]. The only 
consistent finding concerns TP53-mutated subclones, 
which were uniformly shown to increase upon relapse, 
suggesting a fitness advantage under therapeutic selective 
pressure [10, 43].
Analysis of immunoglobulin genes using NGS
The importance of analyzing the molecular 
characteristics of the B cell receptor (BcR) in CLL 
patient management was shown by two seminal studies 
reporting that the immunoglobulin heavy chain (IGH) 
rearrangement’s mutational load can be used as a 
prognosticator, distinguishing patients with a mutated 
BcR (M-CLL) and a more indolent disease course 
from CLL patients bearing unmutated clonotypic BcRs 
(U-CLL) [45, 46]. Subsequent studies shed light onto 
other BcR characteristics in CLL, such as VH-CDR3 
stereotypy [47–51] as well as intraclonal diversification 
in a number of them [52, 53]. The SHM burden is one of 
the strongest prognosticators, but the disease heterogeneity 
is still present among the M-CLL and U-CLL major 
groups. The compartmentalization of CLL patients into 
subsets of stereotypy is a step towards the creation of 
more homogeneous prognostication groups. In fact, 
different subsets of stereotypy not only differ in terms of 
demographics, specific clinical observations and disease 
course [54–56] but also markedly differ in the presence 
or absence of certain genetic lesions (chromosomal or 
recurrent gene mutations). Cases in point are the high 
incidence of SF3B1 mutations in the poor prognostic 
subset #2, or the asymmetric distribution of NOTCH1 
mutations in poor prognostic subsets in contrast to the 
high incidence of MYD88 mutations in patients belonging 
to subsets characterized as prognostically good [57–61]. 
The advancements that massive parallel sequencing 
technologies bring to the field can assist in studying these 
crucial characteristics but also to more sensitively depict 
the immunogenetic background, study clonal diversity and 
dynamics and monitor the disease course [62, 63].
Introducing high-throughput sequencing 
technologies can improve disease monitoring by means of 
minimal residual disease (MRD) detection. Sensitivity in 
MRD detection is a critical issue, since half of the patients 
who have undergone allogeneic stem cell transplantation 
(allo-HCT) experience disease reoccurrence [64, 65], 
albeit associated with being long-term disease-free when 
the examination is negative for one year after allo-HCT 
[66, 67]. Logan et al. [68] reported achieving MRD 
sensitivity detection equal to 1:100,000 molecules. 
They concluded that disease relapses in cases with 
MRD positivity where the malignant clone was present 
in more than 1:100,000 sequences, less than one year 
after-HCT. Boyd et al. [69] successfully identified all 
clonal populations from several samples, to a level of 
1:10,000 copies, and recapitulated the oligoclonal pattern 
of a CLL case, which was shown to exist by means of 
conventional sequencing and capillary electrophoresis 
analysis. Recently, a study was published by the European 
Initiative in CLL [70], where the ClonoSEQ assay for 
MRD detection was compared with flow cytometry 
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approaches and showed successful clone detection at the 
level of 1:10,000 copies.
NGS can also advance studies dealing with clonal 
diversity and intraclonal dynamics issues; Campbell et al. 
[71] attempted to track the evolution of the malignant clone 
by developing a bioinformatics algorithm to distinguish 
true somatic mutations from amplification and sequencing 
errors, based on the analysis of a non-polymorphic locus 
as a control, and reported unexpected intraclonal diversity 
not revealed by previous approaches. Gabriel et al. [72] 
attempted to recapitulate the immunogenetic profile in 
CLL patients. With a 1.6 × 10–4 detection sensitivity, they 
documented specific IG gene combinations with biased 
associations in CLL compared with healthy individuals 
and the intraclonal variation of the mutational burden.
A few studies dealt with the examination of multiple 
productive rearrangements in CLL. Kriangkum et al. 
[73] employed ImmunoSEQ, a multiplex PCR system 
to amplify CDR3 sequences using gDNA as a template 
in 26 CLL patients, to conclude that the allelic exclusion 
mechanism remained active in all cases examined, and 
that the presence of multiple clones is more frequent in 
M-CLL cases.  Furthermore, they documented partner 
clones detected at a frequency greater than 5 × 109 cells/L 
persisted over time despite treatment. More recently, 
Stamatopoulos et al. [74] employed the LymphoTrack 
IGH Somatic Hypermutation Assay Kit by Immunoscribe 
to show that the presence of multiple unrelated productive 
IGH rearrangements in CLL patients exceeds the so far 
estimated frequency, reaching a percentage of almost 
25%. Moreover, based on the mutational status of these 
rearrangements, they categorized the patients into five 
different subgroups and claimed that this categorization 
improves disease stratification and patient management.
Finally, Blachly et al. [75] used next-generation 
RNA sequencing to compute the complete sequence 
of IG transcripts from unselected RNA-seq reads. With 
successful VH CDR3 region acquisition and the mutation 
status of the rearrangements along with a relative 
quantitation of oligoclonal samples they concluded that 
RNA-seq may simultaneously provide multidimensional 
data i.e. gene expression profile, mutation information and 
IGH Somatic hypermutation (SHM) status. 
Sanger sequencing provided an essential image of 
the immunogenetic environment in CLL. The upgrade to 
the NGS era is still in its infancy; virtually all the studies 
so far are limited to analyzing only the heavy chain of the 
BcR. Although mutational status assessment and/or gene 
use in immunoglobulin light chain (IGL) rearrangement 
is not common practice, information about IGH and IGL 
associations could improve the research on CLL ontogeny, 
for example by strengthening the reliability of the 
functional analysis of antibody reactivity. Two individual 
groups attempted to fill that gap by combining single-cell 
PCR with next generation sequencing approaches to deep 
sequence pairs of IG heavy and light chains [76–79].
The 98% cut-off distinguishing M- and U-CLL 
was chosen arbitrarily, and borderline cases were always 
considered to be dealt with carefulness. NGS studies have 
documented the need for a more thorough classification 
[74], especially since there are suggestions for SHM 
analysis to be included in outline clinical tests [80]. This 
dictates the necessity to ensure a precise distinction between 
true somatic mutations and amplification/sequencing 
errors; the latter may generate artificial diversity and 
thus continuous efforts in building algorithms for error 
correction are taking place. However, such error corrections 
must be used with caution since they may inadvertently 
underestimate repertoire diversity by removing rare 
sequences [81]. A lab-bench advancement that may prove 
useful on this track, is the introduction of unique molecular 
identifiers (UMIs) in the sequenced fragments which will 
also assist a more detailed image of the clonal dynamics. To 
this end a methodology proposed by Khan et al. [82] and 
Turchaninova et al. [83] employed the introduction of UMIs 
at the reverse transcription level and applied asymmetrical 
sequencing on seven paired-end CLL libraries constructed 
from a specific number of cells/molecules in order for all 
molecules to be sequenced multiple times; they achieved 
full region sequencing with an estimated error rate of 
1:10,000bp per UMI, since only molecules that were 
sequenced at least ×5 times were evaluated.
Other issues such as the low heterogeneity of IG 
sequences that can affect cluster formation and the biases 
introduced to PCR by the fact that some molecules are 
amplified more than others are currently under the 
spotlight. These issues and experimental set-ups to 
work around them are well-described and discussed by 
Georgiou et al. [84] At the same time the Euroclonality-
NGS consortium has been  established, with its primary 
objective being the development and standardization of 
NGS assays for clonality assessment, MRD analysis and 
repertoire analysis at the pre-analytical (wet-based) and 
post-analytical (bioinformatics) level.
Clinical utilization of NGS in CLL
NGS techniques have provided a better knowledge 
of the genetic complexity underlying the clinical 
heterogeneity of CLL. Most findings indicate a prognostic 
role for some of the new gene mutations and emerging data 
suggest their role in predicting a therapeutic response and 
tracking disease relapse (reviewed in [85]) (Table 1). New 
genomic developments could improve patient outcome 
in two ways: (1) allowing for a more precise prognostic 
estimation and, (2) identifying novel therapeutic targets. 
For the use of prognostication in the clinical setting, 
targeted NGS is particularly suitable as it allows the 
concurrent evaluation of chosen genes, or parts of genes 
that are relevant to a given disease [86]. In addition, it 
is now possible to combine mutation analysis with copy-
number analysis, thereby enabling the simultaneous 
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detection of known copy-number aberrations. Several 
commercially available gene panels have been designed 
to detect either somatic or germline mutations in tumor-
associated genes. As for CLL, there is currently only 
one commercially available CLL-specific gene panel. 
This amplicon-based panel allows single nucleotide as 
well as copy number variant analysis for the nine most 
prognostically relevant genes (Table 2). The efforts to 
design an optimal gene panel that could be widely used 
for CLL prognostication and, more importantly, treatment-
effect prediction, are still on-going. So far, several 
groups have published results for studies employing 
a custom prognostic gene panel intended for clinical 
utilization (Table 2) [87–92]. Some of the recurrently 
mutated genes were common to all gene panels (TP53, 
NOTCH1, SF3B1), while others were found in one study 
only. The first study, reported by Jethwa et al. in 2013, 
used the designed NGS gene panel to study intratumor 
heterogeneity and clonal evolution, and documented the 
presence of convergent mutations [87]. Two other studies 
explored the suitability of NGS gene panels for diagnostic 
purposes [88, 89]. Guieze et al. [90] used their custom 
NGS gene panel to characterize relapsed/refractory CLL 
patients. They reported that concurrent gene mutations 
(“multiple-hit”) are frequent in patients with relapsed/
refractory CLL and are associated with worse outcome. 
Rigolin et al. explored the co-occurrence of mutations 
and other clinical and biological characteristics in patients 
analyzed at diagnosis. They confirmed a negative impact of 
multi-hit profile and they reported association of mutation 
occurrence with adverse molecular and genetic findings 
including IGVH unmutated status, high-risk FISH results, 
and the presence of a complex karyotype [92]. Nadeu et al. 
used a gene panel to study the clinical impact and clonal 
evolution of subclonal mutations [91]. The role of small 
subclonal mutations is a timely question and the study by 
Nadeau et al. together with a report by Rasi et al. [93] 
consistently documented that only subclonal mutations 
in TP53 and not ATM, BIRC3, SF3B1 or NOTCH1 genes 
are of prognostic importance, thus further confirming 
the clinical significance of the small TP53-defective 
subclones suggested by previous studies focusing only on 
TP53 gene [12, 94]. It is therefore now discussed whether 
patients with small TP53-defective subclones should also 
be appointed for non-chemotherapeutic treatment. This 
consideration is extremely important with respect to novel 
targeted therapies that appear to dramatically improve the 
outcome of CLL patients with TP53 defects. To elucidate 
this issue, a prospective study conducted on a uniformly 
treated patient series is desirable.
Prospective multi-institution NGS studies of 
larger patient cohorts will allow us to integrate the newly 
discovered genetic lesions into a comprehensive prognostic 
model based on chromosomal abnormalities, gene mutations 
and also IGHV mutational status. This might improve 
patient prognostication and facilitate the introduction of 
testing into general practice. Efforts to devise an integrated 
prognostic model have already been made [95–97], 
although with partially discordant results, which may 
be related to differences in the design and analysis of the 
studies. Moreover, it is becoming evident that assessing 
the mutational complexity might be more informative than 
dissecting a specific prognosis for each driver as it was 
reported that cumulative number of driver mutations per 
tumor had a progressively worse effect [9, 90, 92].
Despite the still-widening list of prognostically 
significant genes, the only biomarker that influences the 
treatment strategy remains the presence of TP53 defects 
[98], and to date, there has not been enough evidence 
to support the use of NOTCH1, SF3B1, BIRC3 or ATM 
mutations, or CLL subclonal composition in making 
clinical decisions. Prospective trials with larger series 
of patients are needed to stratify CLL patients based on 
these mutations, in order to confirm their clinical impact 
and to address the possible use of these markers to adapt 
treatment. 
Recent works have tried to recapitulate the biological 
consequences of some of the described mutations by 
Table 1: Clinical relevance of the most important mutated genes in CLL patients studied by NGS
Gene mutation Frequency Association with Prognosis References
TP53 5.3–50%* Del (17p13) UM-IGHV Poor 2, 8, 17, 21, 23, 91, 93, 95
ATM 9–23.2% Del (11q23) UM-IGHV Poor 2, 8, 17, 23, 91, 93
RPS15 0.88–19.5% UM-IGHV Poor 9, 10, 21, 23, 45
BIRC3 4–15.5% Del (11q22-q23) UM-IGHV Poor 2, 16, 17, 21, 91, 93
NOTCH1 4–24.1% Trisomy 12 UM-IGHV Poor 11, 17, 18, 21, 23, 45, 91, 93
SF3B1 5–24.9% Del (11q22-q23) ATM mutations UM-IGHV ZAP70 expression Poor 2, 10, 17, 18, 21, 23, 45, 91, 93, 95
MYD88 1.5–10% Del (13q14) M-IGHV Good 2, 8, 10, 16–18, 45, 91, 95
XPO1 1.8–11.5% UM-IGHV Poor? 2, 10, 17, 18, 45, 91, 95
FBXW7 1.3–5% Trisomy 12 Poor 2, 8, 10, 17, 45, 95
SAMHD1 2–9.8% LOH on chromosome 20 Poor? 2, 10, 29, 45, 91
*At the time of diagnosis, TP53 mutations are reported in approximately 5% of patients. On the other hand, in patients with relapsed and refractory CLL, 
the prevalence can be up to 50% of patients.
Oncotarget71241www.impactjournals.com/oncotarget
grouping together genes belonging to the same biological 
pathways, as the genetic activation or silencing of a 
pathway can occur on multiple levels, with a relatively 
consistent effect on the output of the overall pathway [23, 
25, 33, 99]. The presence of recurrent mutations affecting 
the activity of relevant cellular signaling pathways could 
indicate a key role for these mutations in CLL, and 
targeting these genes and pathways could provide effective 
therapy. Future directions should go into understanding the 
pathway map, which could lead to successful targets, as 
it can be witnessed currently in the clinical use of BCR 
signaling inhibitors [100]. Whilst there are currently no 
agents in CLL clinical trials to target NOTCH1 and SF3B1, 
they are clearly promising targets and a number of agents 
targeting these genes and pathways are under development 
[101, 102]. NOTCH1 is a well-established therapeutic 
target in T-cell acute lymphoblastic leukemia (T-ALL), 
while it is possible that splicesome inhibitors could have 
activity against SF3B1 defects.
Conclusions and future directions 
NGS approaches have expanded our knowledge of 
genetic changes in CLL and leukemic clonal architecture, 
and this could have important consequences for prognosis 
and the optimized management of patients. CLL’s 
mutational profile is characterized by a relatively small 
number of somatic mutations per patient, a few recurrent 
mutations at moderate frequency, and a long list of 
recurrent low-frequency mutated genes. The abundance of 
these genomic aberrations in CLL has illustrated its huge 
biological heterogeneity. In fact, these genetic lesions are 
present not only in coding regions but also in non-coding 
regions. The advent of NGS has also allowed us to further 
refine the prognostic impact of IGHV rearrangement, 
enabling the identification of subclones with different IGHV 
rearrangements which would otherwise not be possible with 
Sanger sequencing, considerably less sensitive. 
Technically, the NGS studies have proved the 
applicability, sensitivity and reproducibility of targeted 
sequencing approaches in CLL. However, several aspects 
need to be resolved before NGS can be implemented 
as part of routine diagnostics. Firstly, bioinformatics 
algorithms for data analysis represent an important 
obstacle. At present, multiple commercial as well as 
free software tools are available and many laboratories 
have developed their own in-house methodologies. 
Therefore, the inter-reproducibility of obtained results 
is an issue to be solved, particularly in the case of low-
level subclonal mutations, and studies comparing the 
results obtained by different approaches are warranted 
and ongoing. Secondly, there is currently no agreement 
on the final list of genes to be included in the CLL-
specific prognostication panel. The studies evaluating the 
prognostic impact of mutations in particular genes are to 
some extent contradictory, moreover, new potential driver 
mutations are continually being discovered and the gene 
selection may change with novel targeted therapies as the 
Table 2: Summary of CLL-specific prognostic gene panel designed by different studies
Study Jethwa et al 201387 Sutton et al 2015
88 Vollbrecht et al 
201589
Guieze et al 
201590
Nadeu et al 
201691
Rigolin et al 
201692 Commercially available panel






















MiSeq (Illumina), Ion PGM (Life 
Technologies)
Limit of detection achieved 3% 10% 5% 8%, 30%* 0,3% 5% Depending on samples per run analyzed








ATM ― all coding exons all coding exons not specified exons 2–63 exonic regions all coding exons
BIRC3 ― all coding exons ― not specified exons 2–9 exonic regions all coding exons
MYD88 exons 3, 5 all coding exons all coding exons not specified  exonic regions all coding exons
NOTCH1 exon 34 all coding exons all coding exons not specified exons 26, 27, 34 and 3’UTR exonic regions all coding exons
PIK3CA exons 9, 20 ― exons 9–11, 20–21 ― ― exonic regions ―
SF3B1 exons 14, 15 all coding exons all coding exons not specified exons 14–16 and 18 exonic regions all coding exons
TP53 exons 4–10 all coding exons all coding exons not specified exons 4–10 exonic regions all coding exons

























FBXW7, POT1 (all coding exons)
*Depending on the sequencing depth
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new mechanisms of resistance to these therapies have 
already been emerging. 
The exploitation of NGS in prognostication and 
treatment prediction seems likely to become widespread 
in the near future; however, despite the rapid progress, 
significant work on the validation of new marker 
optimization and harmonizing the process between 
laboratories is still required before it can be used routinely 
in a clinical setting. 
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